---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-007394"
form_type: "8-K"
ticker: "ZEOX"
cik: "0001557376"
company_name: "Zeo ScientifiX, Inc."
filed_at: "2026-07-08T12:00:28+00:00"
generated_at: "2026-07-08T12:05:13.708058+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zeo ScientifiX Q1 FY2026 revenue up 124.6% to $2.58M; net loss narrows to ~$1.0M

## Summary
- Revenue for quarter ended Apr 30, 2026: $2.58M vs $1.15M a year ago, +124.6%.
- Six-month revenue: $4.03M vs $2.24M, +79.9%, driven by allogenic biologic products.
- Gross margins maintained at ~80% for both six-month periods.
- Net loss for six months reduced to ~$1.0M from ~$2.6M in prior-year period.
- CEO cites growing physician adoption and commercial momentum in Florida.

## SEC filing metadata
- accession: 0001829126-26-007394
- form_type: 8-K
- ticker: ZEOX
- cik: 0001557376
- company_name: Zeo ScientifiX, Inc.
- filed_at: 2026-07-08T12:00:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557376/000182912626007394/0001829126-26-007394-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557376/000182912626007394/zeoscientifix_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-007394
- JSON: https://secwatch.observer/filing/0001829126-26-007394.json
- Plain text: https://secwatch.observer/filing/0001829126-26-007394.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.